Fulipiftide
Based on 1 Customer Validation
Fulipiftide (PSP 29-mer) is a short peptide derived from pigment epithelium-derived factor (PEDF). Fulipiftide induces the phosphorylation of ERK2 and STAT3, enriches tendon stem/progenitor cell markers, maintains cell stemness, promotes colony formation and niche expansion, and drives cell infiltration into injured tendons. Fulipiftide promotes the oriented formation of collagen fibers, regulates collagen deposition, and reduces inflammatory cell infiltration and neovascularization. Fulipiftide can be used in studies related to acute tendon injury.
For research use only. We do not sell to patients.
- Purity: 99.38%
- CAS No.: 2868985-56-0
- Formula: C144H227N41O47
- Molecular Weight:3284.59
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
ERK2 |
STAT3 |
Fulipiftide (PSP 29-mer) (10 μM) induces proliferation of nucleostemin-positive tendon stem/progenitor cells from primary rabbit tendon cells via activation of ERK2 and STAT3 signaling pathways[1].
Fulipiftide (10 μM; 10 days) expands tendon stem/progenitor cells (TSPC) from primary rabbit tendon cells by increasing clonogenic capacity and enriching expression of TSPC markers CD146, Oct4, and nestin[1].
Fulipiftide (10 μM; 10 days) expanded tendon stem/progenitor cells from primary rabbit tendon cells retain the capacity for tenogenic differentiation, as shown by increased expression of tenocyte lineage-related genes after peptide withdrawal[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, 10 weeks old, initial body weight 312 g)[1]
-
Dosage:100 μM
-
Administration:subcutaneous injection; single dose
-
Result:Increased CD146+ TSPC count to 61.4 per microscope field in the peripheral tendon region at 2 days post-surgery.
Increased BrdU co-labeling rate of CD146+ TSPC to 32.4% at 2 days post-surgery.
Increased CD146+ TSPC count to 59.6 per microscope field in the healing region at 7 days post-surgery.
Increased BrdU co-labeling rate of nucleostemin+ TSPC to 15.8% at 7 days post-surgery.
Achieved 89.1% of the ultimate tensile stress and 89.3% of the Young’s modulus of contralateral intact tendons at 3 weeks post-surgery.
Reduced histological scores for fiber arrangement, fiber structure, nuclear roundness, inflammatory cell/fibroblast infiltration, and neoangiogenesis compared to vehicle controls at 3 weeks post-surgery.
Induced densely aligned collagen fibers, reduced inflammatory cell invasion, fewer neovessels, stronger type I collagen expression, and type III collagen expression similar to intact tendons at 3 weeks post-surgery.
Chemical Information
-
CAS No. 2868985-56-0
-
Appearance Solid
-
Molecular Weight 3284.59
-
Formula C144H227N41O47
-
Color White to off-white
-
Synonyms
PSP 29-mer, anti-inflammatory peptide
-
Sequence
Ac-Ser-Leu-Gly-Ala-Glu-Gln-Arg-Thr-Glu-Ser-Ile-Ile-His-Arg-Ala-Leu-Tyr-Tyr-Asp-Leu-Ile-Ser-Ser-Pro-Asp-Ile-His-Gly-Thr-NH2
-
Sequence Shortening
Ac-SLGAEQRTESIIHRALYYDLISSPDIHGT-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 50 mg/mL (15.22 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.3045 mL | 1.5223 mL | 3.0445 mL | 7.6113 mL |
| 5 mM | 0.0609 mL | 0.3045 mL | 0.6089 mL | 1.5223 mL | |
| 10 mM | 0.0304 mL | 0.1522 mL | 0.3045 mL | 0.7611 mL | |
| 15 mM | 0.0203 mL | 0.1015 mL | 0.2030 mL | 0.5074 mL |
Fulipiftide Related Classifications
HY-P10953 Related Classifications
Powered by Bioz